Spyre Therapeutics, Inc. SYRE
85.69
(1.40)
(1.61%)
as of 25 Sep
- Market cap
- $7.7B
- P/E
- 0.0×
Follow SYRE
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
756.53 | 603.09 | 339.28 | 55.71 | 93.13 | 146.27 | 71.95 | 74.51 | 50.30 | 63.50 |
Receivables |
— | — | — | 0.38 | 0.82 | — | — | 0.30 | 3.08 | 1.22 |
Total current assets |
777.78 | 608.47 | 341.53 | 62.26 | 98.89 | 149.79 | 74.51 | 76.67 | 54.99 | 66.42 |
Property, Plant, Equpment (Net) |
— | — | — | 3.22 | 4.55 | 5.64 | 2.39 | 1.02 | 0.85 | 0.60 |
Long-term assets (Other) |
— | 0.01 | 0.33 | 2.24 | 2.68 | 1.96 | 1.57 | 0.05 | 0.23 | 0.04 |
Total non-current assets |
— | 0.01 | 0.33 | 8.89 | 11.04 | 11.83 | 8.68 | 1.07 | 1.09 | 0.64 |
Total Assets |
777.78 | 608.48 | 341.86 | 71.14 | 109.93 | 161.62 | 83.18 | 77.74 | 56.08 | 67.06 |
Accounts Payable |
8.90 | 0.67 | 0.90 | 0.68 | 3.32 | 2.25 | 3.15 | 0.66 | 0.39 | 0.17 |
Accrued Expenses |
26.95 | 27.71 | 13.11 | 12.84 | 14.03 | 13.87 | 14.85 | 9.58 | 5.22 | 3.73 |
Current Revenue (Deferred) |
— | — | 0.00 | 0.52 | 2.36 | 0.00 | — | — | 0.02 | 0.07 |
Other current liabilities |
22.82 | 25.08 | 1.39 | 13.34 | 15.97 | 13.84 | 14.83 | 9.58 | 5.24 | 3.80 |
Total current liabilities |
58.69 | 54.06 | 31.98 | 14.66 | 20.14 | 16.44 | 18.36 | 10.24 | 5.63 | 3.97 |
Non-current Revenue (Deferred) |
— | — | 0.00 | 2.18 | 1.22 | 0.00 | — | — | — | — |
Preferred Shares of Subsidiary (Mandatory, Redeemable) |
— | — | 84.56 | 0.00 | — | — | — | — | — | — |
Non-current Liabilities (Other) |
3.86 | 36.62 | 41.31 | — | 0.02 | 0.21 | 0.03 | 0.07 | 0.11 | 0.13 |
Total non-current liabilities |
3.86 | 36.62 | 125.87 | 6.18 | 5.84 | 5.34 | 4.74 | 0.07 | 0.11 | 0.13 |
Total liabilities |
62.55 | 90.68 | 157.84 | 20.84 | 25.99 | 21.79 | 23.10 | 10.31 | 5.74 | 4.10 |
Additional Paid In Capital |
1,686.17 | 1,334.22 | 763.19 | 475.97 | 425.77 | 415.82 | 255.14 | 184.31 | 122.95 | 108.25 |
Preferred Stock (Total) |
155.82 | 155.82 | 184.93 | — | — | — | — | — | — | — |
Common Stock (Net) |
0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(1,127.63) | (972.43) | (764.41) | (425.62) | (341.81) | (276.01) | (195.11) | (116.86) | (72.51) | (45.28) |
Common Equity (Total) |
559.42 | 361.98 | (0.91) | 50.31 | 83.94 | 139.83 | 60.08 | 67.43 | 50.34 | 62.97 |
Shareholders Equity (Total) |
715.24 | 517.80 | 184.02 | 50.31 | 83.94 | 139.83 | 60.08 | 67.43 | 50.34 | 62.97 |
Shareholders Equity and Liabilities (Total) |
777.78 | 608.48 | 341.86 | 71.14 | 109.93 | 161.62 | 83.18 | 77.74 | 56.08 | 67.06 |
Shares (Common) |
78.19 | 60.26 | 36.06 | 2.61 | 1.97 | 1.92 | 1.16 | 0.97 | 0.67 | 0.54 |
Shares (Preferred) |
0.62 | 0.36 | — | — | — | — | — | — | — | — |
Shareholders Equity (Tangible) |
715.24 | 517.80 | 184.02 | 50.31 | 83.94 | 139.83 | 60.08 | 67.43 | 50.34 | 62.97 |
Net Debt |
(756.53) | (603.09) | (339.28) | (55.71) | (93.13) | (146.27) | (71.95) | (74.51) | (50.30) | (63.50) |
Total Debt |
— | — | — | 4.65 | 5.48 | 5.52 | 5.12 | — | — | — |
In millions of $ except per-share values · columns are period end dates